Ongoing trials

High-Risk Smoldering Myeloma

(no trials in this category at the moment)

Newly Diagnosed Multiple Myeloma

EMN39 LUMYNA: A Randomized, Open-Label, Controlled Phase 3 Study Comparing Daratumumab, Lenalidomide and Dexamethasone Induction followed by Linvoseltamab Versus continued Daratumumab, Lenalidomide, and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma Patients

M25-059: A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects with Multiple Myeloma (this trial may include both newly diagnosed and relapsed/refractory multiple myeloma)

Relapsed/Refractory Multiple Myeloma

CA057-1040: A Phase 1b/2a, Multicenter, Open-label Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination with Elranatamab in Participants with Relapsed and/or Refractory Multiple Myeloma

Trilogy-4: A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody

ACT: Phase 1/2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma

CA057-003: Phase 1b/2a study to evaluate mezigdomide in combination with other treatments in relapsed or refractory multiple myeloma

TRIgnite-1: A Phase 1, open-label study to evaluate the safety and anti-myeloma activity of ISB 2001, a BCMAxCD38xCD3-targeting trispecific antibody, in participants with relapsed/refractory multiple myeloma

M24-555: Phase 1/2 study of Etentamig (a BCMAxCD3-targeting bi-specific antibody) in combination with a CELMoD agent for the treatment of patients with relapsed/refractory multiple myeloma